Jun 28th, 2010 | By Vigilant | Category: Vigilant Reports
Is there a deliberate effort by the government to dumb down the masses? The statement is hard to prove but there exists a great amount of data proving that the ruling elite not only tolerates, but effectively introduces policies that have a detrimental effect on the physical and mental health of the population. This series of articles looks at the many ways the modern man is being dumbed down. Part I looks at the poisons found in everyday foods, beverages and medications.
The theme of dumbing-down and dehumanizing the masses are often discussed in articles on The Vigilant Citizen. The presence of those concepts in popular culture are, however, only the outward and symbolic expression of the profound transformation happening in our society. Scientific data has been proving for years that governments around the world are tolerating the selling of many products which have a direct and negative effect on cognitive and physical health. As we will see in this article many everyday products cause brain damage, impaired judgment and even a lower IQ.
Is a dumber population something that is desired by the elite? Hitler once said “How fortunate for the leaders that men do not think.” An educated population knows its rights, understands the issues and takes action when it does not approve of what is going on. Judging by the incredible amount of data available on the subject, it seems that the elite want the exact opposite: an unhealthy, frightened, confused and sedated population. We will look at the effects of medication, pesticides, fluoride and aspartame on the human body and how those products are being pushed by people from inside the power structure.
Prescription Drug Abuse
America has witnessed during the last decades a staggering rise of drugs being prescribed to treat all kinds of problems. Children are particularly affected by this phenomenon. Since the 1990′s, an ever-rising proportion of American children are being diagnosed with “illnesses” such as Attention Deficit Disorder (ADD) and are prescribed mind-altering drugs, such as Ritalin.
The DEA has become alarmed by the tremendous increase in the prescribing of these drugs in recent years. Since 1990, prescriptions for methylphenidate have increased by 500 percent, while prescriptions for amphetamine for the same purpose have increased 400 percent. Now we see a situation in which from seven to ten percent of the nation’s boys are on these drugs at some point as well as a rising percentage of girls.
Today, children who show too much energy, character or strength are being willfully sedated with powerful drugs which directly affect the way their brains function. Are we going in the right direction here?
Even if ADD is not a clearly defined and documented disorder – it causes NO observable biological effects whatsoever – children are still being diagnosed with the illness in great numbers. This raises important ethical questions.
“Pediatricians as well as ethicists have also voiced their concerns in usage of these stimulants. In an article published in the New York Times, they have questioned the appropriateness of medicating children without a clear diagnosis in hopes that they do better in school. They also asked whether the drugs should be given to adults failing in their careers or are procrastinators. They question the worthy of this method.
This concern have also been voiced out in the January 2005 issue of Pediatrics in which the large discrepancies between pediatricians’ practice patterns and the American Academy of Pediatrics (AAP) guidelines for the assessment and treatment of children with attention-deficit/hyperactivity disorder (ADHD) was bought forth. The article also stated that because the medical community didn’t come to a consensus on how to diagnose ADD/ADHD, they should not be making extensive decisions as to how to treat individuals who have been diagnosed with the disorder.”
The usage of Ritalin at a young age breaks the psychological threshold people maintain towards the usage of prescription pills, which makes those children more likely to consume psychotropic drugs later in their lives. We should not be surprised to witness a dramatic increase of consumption of antidepressants in the years to come. The trend is already beginning:
“In its study, the U.S. Centers for Disease Control and Prevention looked at 2.4 billion drugs prescribed in visits to doctors and hospitals in 2005. Of those, 118 million were for antidepressants.
The use of antidepressants and other psychotropic drugs — those that affect brain chemistry — has skyrocketed over the last decade. Adult use of antidepressants almost tripled between the periods 1988-1994 and 1999-2000. Between 1995 and 2002, the most recent year for which statistics are available, the use of these drugs rose 48 percent, the CDC reported.”
- Elizabeth Cohen, CNN
The use of prescription pills might be of a great help for specific and properly diagnosed cases. The pharmaceutical industry however, which has many “friends” in the highest levels of government, is pushing for the widespread use of psychiatric drugs within the public. Since 2002, a great number of pills claiming to fix all kinds of mental conditions have been marketed to the public, but many of those pills were approved for sale without proper research for side effects. Even worse: the side effects might have been known but hidden to the public. Below is a list of warnings issued on commonly sold psychiatric drugs. Some of those side effects are actually frightening as a pill should not be able to have that much power over the human brain. Think about it: Some drugs are subject to warnings because they can cause you to … commit suicide?
March 22: The Food and Drug Administration (FDA) warned that Prozac-like antidepressants (called Selective Serotonin Reuptake Inhibitors or SSRIs) could cause “anxiety, agitation, panic attacks, insomnia, irritability, hostility, impulsivity, akathisia [severe restlessness], hypomania [abnormal excitement] and mania [psychosis characterized by exalted feelings, delusions of grandeur].”
June: The Therapeutic Goods Administration, the Australian equivalent of the FDA, reported that the latest antipsychotic drugs could increase the risk of diabetes.
June: The FDA ordered that the packaging for the stimulant Adderall include a warning about sudden cardiovascular deaths, especially in children with underlying heart disease.
October 15: The FDA ordered its strongest “black box” label for antidepressants warning they could cause suicidal thoughts and actions in under those under 18 years old.
October 21: The New Zealand Medicines Adverse Reactions Committee recommended that older and newer antidepressants not be administered to patients less than 18 years of age because of the risk of suicide.
December 17: The FDA required packaging for the “ADHD” drug, Strattera, to advise that “Severe liver damage may progress to liver failure resulting in death or the need for a liver transplant in a small percentage of patients.”
February 9: Health Canada, the Canadian counterpart of the FDA, suspended marketing of Adderall XR (Extended Release, given once a day) due to reports of 20 sudden unexplained deaths (14 in children) and 12 strokes (2 in children).
April 11: The FDA warned that antipsychotic drug use in elderly patients could increase the risk of death.
June 28: The FDA announced its intention to make labeling changes to Concerta and other Ritalin products to include the side effects: “visual hallucinations, suicidal ideation [ideas], psychotic behavior, as well as aggression or violent behavior.”
June 30: The FDA warned that the antidepressant Cymbalta could increase suicidal thinking or behavior in pediatric patients taking it. It also warned about the potential increased risk of suicidal behavior in adults taking antidepressants.
August: The Australian Therapeutic Goods Administration found a relationship between antidepressants and suicidality, akathisia (severe restlessness), agitation, nervousness and anxiety in adults. Similar symptoms could occur during withdrawal from the drugs, it determined.
August 19: The European Medicines Agency’s Committee for Medicinal Products warned against child antidepressant use, stating that the drugs caused suicide attempts and thoughts, aggression, hostility, aggression, oppositional behavior and anger.
September 26: The Agenzia Italiana del Farmaco (Italian Drug Agency, equivalent to the FDA) warned against use of older (tricyclic) antidepressants in people under 18 years old. It also determined the drugs were associated with heart attacks in people of any age.
September 29: The FDA ordered that labeling for the “ADHD” drug Strattera include a boxed warning about the increased risk of suicidal thinking in children and adolescents taking it.
October 17: The FDA warned that the antidepressant Cymbalta could cause liver damage.
October 24: The FDA withdrew the stimulant Cylert from the market because of the risk of liver toxicity and failure.
November: The FDA warned that the antidepressant Effexor could cause homicidal thoughts.
February 9: The FDA’s Drug Safety and Risk Management Advisory Committee urged that the strongest “black box” warning be issued for stimulants, because they may cause heart attacks, strokes and sudden death.
February 20: British authorities warned that Strattera was associated with seizures and potentially lengthening period of the time between heartbeats.
March 22: An FDA advisory panel heard evidence of almost 1,000 reports of kids experiencing psychosis or mania while taking stimulants.
May 3: FDA adverse drug reaction reports linked antipsychotic drugs to 45 child deaths and 1,300 serious adverse reactions, such as convulsions and low white blood cell count.
May 12: The manufacturer of Paxil warned that the antidepressant increases the risk of suicide in adults.
May 26: Health Canada issued new warnings of rare heart risks for all drugs prescribed for “ADHD,” including the risk of sudden death.
June 2: An FDA study determined that the antipsychotic drug, Risperdal, might cause pituitary tumors. The pituitary gland, at the base of the brain, secretes hormones that promote growth, and regulates body functions. Antipsychotics may increase prolactin, a hormone in the pituitary gland, and this increase has been linked to cancer. Risperdal was found to increase prolactin levels more frequently than in other antipsychotics.
July 19: The FDA said antidepressant packaging should carry warnings that they may cause a fatal lung condition in newborns whose mothers took SSRI antidepressants during pregnancy. Migraine sufferers also need to be warned that combining migraine drugs with SSRIs could result in a life-threatening condition called serotonin syndrome.